Bayer terminated a two-year-old partnership with Atara Biotherapeutics that included the development of off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
AbbVie terminated the company’s collaboration agreement with BioArctic in the development of alpha-synuclein antibodies for Parkinson’s disease and other movement disorders.
Roche and Atea Pharmaceuticals are terminating their partnership to develop and commercialize a Covid-19 antiviral effective February 10, 2022.
Two years after AbbVie and Voyager Therapeutics first forged a collaboration to develop treatments for Alzheimer’s disease, the partnership came to an end after AbbVie terminated the agreement.
A Biogen employee with symptoms of the novel coronavirus COVID-19 was terminated by the company after she left her home in Massachusetts and boarded a plane to China without disclosing her exposure to the virus.
Lexicon Pharmaceuticals Inc. said France’s Sanofi SA will pay the Texas-based drugmaker $260 million for the termination of their partnership to develop the diabetes drug Zynquista.